If gene-editing tomatoes proves effective, researchers hope to bring the first “sunshine tomato” to market within three years ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
Leiden researchers, led by Sebastian Pomplun, have developed a new method to screen hundreds of thousands of molecules for ...
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc ...
6d
Clinical trial presents promising DNA-encoded therapy for long-lasting protection against COVID-19
A new way to deliver protective antibodies against COVID-19 was tested in a Phase I clinical trial. Instead of injecting ...
Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...
Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...
Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...
Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...
The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback